HPV vaccine trial for oropharyngeal cancer patients
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a therapeutic vaccine for people with HPV16-positive oropharyngeal cancer who have finished curative treatment and are free of disease. The vaccine aims to help the immune system prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with HPV16-positive oropharyngeal cancer.
- You must have completed all curative treatment (surgery, radiation, or chemo) at least 16 weeks ago, with no current signs of cancer.
- You need to be in good overall health, as measured by your ability to perform daily activities (ECOG 0 or 1).
- You must agree to use effective contraception for at least 4 months after the last vaccine dose if you or your partner could become pregnant.
- You cannot have a serious autoimmune disease, active infection, or be on high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks whether a blood test for HPV16 DNA can predict when HPV-related throat cancer comes back after treatment. It may help improve follow-up care by catching recurrence earlier.
This trial tests a new immunotherapy called FluBHPVE6E7 for people with HPV16-positive oropharyngeal cancer that has not spread to distant parts of the body. The treatment is given directly into the tumor to help the immune system fight the cancer.
This trial tests a new combination of immunotherapy drugs and an HPV vaccine alongside chemotherapy and radiation for throat cancers caused by HPV. The goal is to see if this approach works as well as standard treatment while using less radiation, potentially reducing side effects.
This trial tests whether radiation or chemoradiation works well for HPV-positive throat cancer. It may be an option if you have this type of cancer and are getting or have already had surgery.
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
Hear when a new Head and Neck Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.